Bill Gates-backed Triangle startup targeting Alzheimer’s treatment raises $6M
An RTP based drug development firm backed by a Bill Gates-linked foundation has raised more than $6 million as it continues to develop an Alzheimer’s treatment.
Read More
T3D Therapeutics
Bill Gates, Alzheimer’s Association provide $740K grant to RTP startup
T3D Therapeutics, a life science startup seeking to develop a treatment for Alzheimer’s disease, has another $740,000 to use in pursuit of its research courtesy of the Alzheimer’s Association and its partner Bill Gates.
Read More
Ten Alzheimer’s experts join T3D Therapeutics as scientific advisors
The creation of the new Scientific Advisory Board coincides with the company’s launch of a Phase 2 clinical trial of its leading drug candidate, T3D-959, an oral medication intended for patients with mild to moderate Alzheimer’s disease.
Read More
RTP-based startup T3D offers hope to Alzheimer’s patients
T3D Therapeutics, a 7-year-old company started with loan help from the North Carolina Biotechnology Center, said today it is launching a Phase 2 clinical trial with its unique product candidate, T3D-959, to treat mild to moderate forms of Alzheimer’s disease (AD).
Read More
Emerging RTP drug firm lands $9M grant to drive Alzheimer’s research (+ video)
T3D Therapeutics, a Research Triangle Park company started with loan help from the North Carolina Biotechnology Center, has received a four-year federal grant expected to total $9 million to help study the company’s promising approach for battling Alzheimer’s disease.
Read More
24 life science firms backed by NC Biotech Center raise $115M in follow-on funding
Two dozen bioscience companies that previously received loans from the Biotech Center raised about $115 million in follow-on funding from other sources in the last two quarters.
Read More
Innovative Alzheimer’s drug developer T3D Therapeutics injects $700K of a debt offering
RTP-based T3D Therapeutics, which is developing a treatment for Alzheimer’s that has the potential to slow, stop or reverse the course of the disease, has raised more than $700,000 of $1 million debt offering, according to a filing with the US Securities and Exchange Commission.
Read More
